Uncoupling Cardiotoxicity: A TNF-Driven Mechanism Behind Immunotherapy’s Heart Risk
A pivotal study in cell biology and immunology has identified the precise molecular mechanism behind a severe side effect of cancer immunotherapy. Immune checkpoint inhibitors (ICIs), which block proteins like CTLA-4 and PD-1 to unleash T cells against tumors, can trigger fatal myocarditis. Using a novel mouse model with cardiomyocyte-restricted antigen expression, researchers demonstrated that combined αCTLA-4 and αPD-1 blockade drives robust expansion of autoreactive CD8+ T cells, leading to myocardial inflammation and lethal arrhythmias. Crucially, the research found that this cardiac injury is not mediated by perforin-based cytotoxicity but is critically dependent on CD8 T cell–derived tumor necrosis factor (TNF) signaling through TNF receptor 2 (TNFR2). This TNF-TNFR2 axis promotes myeloid cell recruitment and cytokine production, establishing a central inflammatory circuit for the pathology.
Study Significance: This discovery in cell signaling and immune regulation provides a clear therapeutic target to mitigate a major clinical hurdle in oncology. For professionals in cancer cell biology and immunotherapy development, it suggests that blocking the TNF-TNFR2 pathway could prevent cardiotoxicity while preserving the crucial antitumor efficacy of immune checkpoint blockade. This strategic uncoupling of efficacy from toxicity could directly influence the design of next-generation combination therapies and improve patient safety profiles in clinical practice.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
